Literature DB >> 12359422

Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.

Anil Kumar1, Sampa Mukherjee, Jing Shen, Shilpa Buch, Zhuang Li, Istvan Adany, Zhenqian Liu, Wu Zhuge, Michael Piatak, Jeffrey Lifson, Harold McClure, Opendra Narayan.   

Abstract

To evaluate the vaccine potential of SHIVs attenuated by deletion of viral accessory genes, seven rhesus macaques were sequentially immunized with Delta vpu Delta nefSHIV-4 (vaccine-I) followed by Delta vpuSHIV(PPC) (vaccine-II). Despite the absence of virological evidence of productive infection with the vaccine strains, based on analysis of infectivity among peripheral blood mononuclear cells (PBMC) of the vaccinated animals, all seven animals developed binding as well as neutralizing antibodies against both vaccine-I and -II. The animals also developed vaccine virus-specific CTLs that recognized homologous as well as heterologous pathogenic SHIVs and SIV, and also soluble inhibitory factors that blocked the in vitro replication of the vaccine strains and different challenge viruses. Virus-specific cellular and humoral responses were sustained throughout a 58-week prechallenge period. To model aspects of natural transmission, the animals received a mucosal (rectal) challenge, with a mixture of three challenge viruses, SHIV(KU), SHIV(89.6)P, and SIV(mac)R71/17E. Two mock-vaccinated control animals inoculated with the same mixture of challenge viruses developed large numbers of infectious PBMC, high plasma viremia, and precipitous loss of CD4(+) T cells. The control animals did not develop any immune responses and succumbed to AIDS between 6 and 7 weeks postchallenge. All seven vaccinated animals became infected with challenge viruses as indicated by the presence of infectious cells in the PBMC and/or viral RNA in plasma. However, peak plasma viremia in vaccinates was two to nearly five logs lower than in the control animals and later plasma viral RNA became undetectable in all vaccinates. Vaccinated animals maintained normal CD4(+) T cell levels throughout the study. Challenge with pathogenic viruses caused massive anamnestic responses as determined by quantitation of virus-specific CD4(+) and CD8(+) T cells by intracellular IFN-gamma staining, and these cells persisted for at least 74 weeks. The study is still in progress and at this time DNA of SIV has become undetectable in lymph nodes of six of the seven vaccinates, SHIV(89.6)P in five of the seven, and SHIV(KU) in three of the seven animals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359422     DOI: 10.1006/viro.2002.1544

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  SIV Vpr evolution is inversely related to disease progression in a morphine-dependent rhesus macaque model of AIDS.

Authors:  Richard J Noel; Anil Kumar
Journal:  Virology       Date:  2006-10-24       Impact factor: 3.616

2.  Protection of macaques against AIDS with a live attenuated SHIV vaccine is of finite duration.

Authors:  Anil Kumar; Zhenqian Liu; Darlene Sheffer; Marilyn Smith; Dinesh K Singh; Shilpa Buch; Opendra Narayan
Journal:  Virology       Date:  2007-11-07       Impact factor: 3.616

3.  DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory.

Authors:  Mariana Manrique; Ewa Micewicz; Pamela A Kozlowski; Shainn-Wei Wang; Deepti Aurora; Robert L Wilson; Musie Ghebremichael; Gail Mazzara; David Montefiori; Angela Carville; Keith G Mansfield; Anna Aldovini
Journal:  AIDS Res Hum Retroviruses       Date:  2008-03       Impact factor: 2.205

4.  Envelope variation as a primary determinant of lentiviral vaccine efficacy.

Authors:  Jodi K Craigo; Baoshan Zhang; Shannon Barnes; Tara L Tagmyer; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-10       Impact factor: 11.205

5.  Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques.

Authors:  Jörn E Schmitz; R Paul Johnson; Harold M McClure; Kelledy H Manson; Michael S Wyand; Marcelo J Kuroda; Michelle A Lifton; Rajinder S Khunkhun; Kimberly J McEvers; Jacqueline Gillis; Michael Piatak; Jeffrey D Lifson; Gudrun Grosschupff; Paul Racz; Klara Tenner-Racz; E Peter Rieber; Kristine Kuus-Reichel; Rebecca S Gelman; Norman L Letvin; David C Montefiori; Ruth M Ruprecht; Ronald C Desrosiers; Keith A Reimann
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.

Authors:  Mauro Pistello; Donatella Matteucci; Francesca Bonci; Patrizia Isola; Paola Mazzetti; Lucia Zaccaro; Antonio Merico; Daniela Del Mauro; Norman Flynn; Mauro Bendinelli
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Control of viremia and maintenance of intestinal CD4(+) memory T cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge.

Authors:  Bapi Pahar; Andrew A Lackner; Michael Piatak; Jeffrey D Lifson; Xiaolei Wang; Arpita Das; Binhua Ling; David C Montefiori; Ronald S Veazey
Journal:  Virology       Date:  2009-03-18       Impact factor: 3.616

8.  Modulation by morphine of viral set point in rhesus macaques infected with simian immunodeficiency virus and simian-human immunodeficiency virus.

Authors:  Rakesh Kumar; Cynthia Torres; Yasuhiro Yamamura; Idia Rodriguez; Melween Martinez; Silvija Staprans; Robert M Donahoe; Edmundo Kraiselburd; Edward B Stephens; Anil Kumar
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

9.  Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239.

Authors:  Kristina Abel; Tracy Rourke; Ding Lu; Kristen Bost; Michael B McChesney; Christopher J Miller
Journal:  J Infect Dis       Date:  2004-09-24       Impact factor: 5.226

10.  Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge.

Authors:  John Schell; Nina F Rose; Nicole Fazo; Preston A Marx; Meredith Hunter; Elizabeth Ramsburg; David Montefiori; Patricia Earl; Bernard Moss; John K Rose
Journal:  Vaccine       Date:  2009-01-07       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.